Our findings provide insight into the importance of the VEGF-A/VEGFR2/NRP1 signaling pathway inhibition to improve anti-angiogenic therapy and suggest it could be a promising approach to breast cancer treatment. The gene discussed is NRP1; the disease is breast carcinoma.